Nicotinamide Mononucleotide (NMN) – Sabon Maganar Tsawon Rai

NMN ya zama ɗaya daga cikin ƙwayoyin da aka fi tattaunawa a fannin tsawon rai, musamman game da ƙara matakin NAD+, makamashi, da kuma tsufa mai lafiya. Binciken meta‑analysis da aka wallafa a Nutrients (Zhang et al., 2026) ya duba tambaya mai sauƙi: shin NMN na iya rage matsi na jini a mutanen da matsin su ya riga ya ɗaga? Amsa, da ƙwazo, ba a bayyana sosai ba – amma alama mafi ƙarfi ta bayyana a manyan da suka kai shekaru 60 da sama.

Menene Masu Binciken Suka Yi?

Ƙungiyar ta duba manyan bayanai na PubMed/MEDLINE, Scopus, Web of Science da EBSCO har zuwa 13 Disamba 2025 don nemo gwaje‑gwajen da aka gudanar a matsayin randomized controlled trials (RCTs) na NMN da suka yi rahoton matsi na jini a hutu. Sun haɗa bayanai daga gwaje‑gwaje 10, da suka ƙunshi ƙungiyoyi 11 da mahalarta 349, inda aka kwatanta NMN da placebo.

Sakamakon an ƙara amfani da samfurin “common‑effects” a cikin R. Daga nan sai suka yi ƙididdiga bisa ga rukunin shekaru, nauyi (BMI), ƙasa, tsawon lokacin tsangwama, da ƙimar NMN da ake amfani da ita.

Sakamakon Da Aka Tabbata

• Matsi na diastolic (DBP): NMN ya kawo ragi mai ma’ana amma ƙanƙanta na ‑2.15 mmHg (95 % CI: ‑3.68 zuwa ‑0.61) idan aka kwatanta da placebo.
• Matsi na systolic (SBP): Ba a samu ragi da ya kai ga muhimmin bambanci ba a gaba ɗaya.
• Maza/’yan mata masu shekaru 60 da sama: A cikin ƙungiyar wannan rukunin, SBP ya sauka da ‑3.94 mmHg (95 % CI: ‑7.06 zuwa ‑0.82).

Kodayake ƙananan ragi a SBP sun bayyana ne kawai a manyan da suka wuce shekaru 60, interval na amincewa ya yi fadi sosai – daga ragin kusan 7 mmHg har zuwa ƙarami fiye da 1 mmHg – abin da ke nuna cewa sakamakon na iya kasancewa tsakanin babu tasiri da tasiri mai ƙarfi.

Ragi Na 2‑4 mmHg – Me Ke Nufi A Rayuwa?

Ragin kimanin 2 mmHg a diastolic yana da muhimmanci a bangaren kididdiga, amma a ainihin rayuwa ƙanana ne. Don kwatanta, magungunan antihypertensive na al’ada kan rage systolic da dama‑dama, kuma sauye‑sauyen rayuwa kamar rage gishiri, rage kitsen jiki, da motsa jiki na iya haifar da canje‑canje masu girma.

Manazarta sun bayyana sakamakon a matsayin “na farkon bincike da alama”. Wannan ba yana nufin NMN zai maye gurbin maganin matsi na jini ba, kuma babu wani hujja a wannan nazari da ke goyon bayan dakatar da magani ko canza shi.

Dalilin Da Yasa Alamar Ga Manya Sama Da Shekaru 60 Tafi Mai Ban Sha’awa Amma Ba Ta Da Karfi

Akwai hujja mai ma’ana a kimiyya: matakan NAD+ sukan ragu da shekaru, kuma NAD+ yana da alaƙa da aikin jijiyoyi, lafiyar mitochondria, da amsar sel a ga damuwa. Idan NMN ke ƙara samar da NAD+, manya – musamman waɗanda suka fara da ƙananan matakai – na iya amsawa fiye da matasa. Wannan ra’ayi ya yi kyau, amma binciken nan ba zai iya tabbatar da shi ba.

Ƙalubale Da Ke Gaban Gaba:

• Karamin adadin mahalarta. Da mahalarta 349 a cikin gwaje‑gwaje 10, kowanne ƙungiya ta zama ƙanana, don haka sakamakon na iya fuskantar girman ƙuruciya.
• Bambancin sakamako a SBP. Ragin SBP ba ya kai ga bambanci mai ma’ana gaba ɗaya; an ga ragin kawai a ƙungiyar masu shekaru 60 da sama.
• Samfurin “common‑effects”. Wannan yana ɗauka duk gwaje‑gwaje suna da tasiri guda ɗaya; idan akwai bambance‑bambance a tsawon lokaci, ƙimar NMN, ko al’ummomin da aka gwada, samfurin “random‑effects” ne yafi dacewa.
• Dabarun gwaje‑gwaje daban‑daban. Amfani da ƙwayoyi da ƙima daban‑daban na NMN na iya ɓoye bambance‑bambancen da ke tsakanin gwaje‑gwaje.

Adadi Da Tsawon Lokaci

Taƙaitaccen bayani ya nuna an yi nazari bisa ga adadi da tsawon lokacin tsangwama, amma ba a bayar da takamaiman lambobi ba. Bisa ga asalin takarda, adadi da tsawon lokacin suna bambanta a cikin gwaje‑gwaje. Masu sha’awar ƙarin bayani su duba takardar asali.

Waɗanda Zasu Iya Amfana Da Wannan Nazari

• Manyan mutane, musamman masu shekaru 60 da sama, da ke neman NMN don inganta lafiya yayin tsufa.
• Mutanen da ke da matsi na jini mai ɗan ƙaruwa kuma suna neman ƙarin taimako a ƙarƙashin kulawar likita.
• Masu bincike da ke shirya manyan gwaje‑gwaje na NAD+ precursors.

Bai da tasiri sosai ga mutanen da ke da matsi na jini a matakin da ya dace ba, kuma ba hujja ba ce don magance hypertension da NMN kaɗai.

Abubuwan Da Ba Mu Da Tabbas Din Su

Manazarta sun kira manyan gwaje‑gwaje na dogon lokaci, masu girma, da ingantattu. Tambayoyin da ke buƙatar amsa sun haɗa da:

• Shin tasirin zai ci gaba bayan shekaru masu yawa na amfani da NMN?
• Shin NMN na haifar da wasu kurakuran zuciya?
• Yaya NMN zai kwatanta da sauran NAD+ precursors kamar nicotinamide riboside?
• Wane rukunin majiyyaci ne zai fi amfana?

Auna matsi a gida ko a cikin 24‑hour ambulatory a ƙarin gwaje‑gwaje zai taimaka wajen tantance ainihin tasirin daga shigo da hayaniyar ma’aunin a asibiti.

Abubuwan Da Za a Iya Aiwatarwa

• Tasirin na ƙanƙanta. Kimanin ‑2.15 mmHg a diastolic yana da ma’ana a ƙididdiga amma ƙanana ne a zahiri.
• SBP gaba ɗaya bai canza ba. Ragin ‑3.94 mmHg na systolic ya bayyana ne kawai a rukunin masu shekaru 60 da sama.
• Shaidar tana da farawa. Gwaje‑gwaje 10 da mutane 349 su ne tushen iyaka, kuma marubutan sun bayyana sakamakon a matsayin na farko.
• NMN ba maganin matsi ne. Kada a maye gurbin ko a rage maganin da aka ba da shi bisa ga wannan nazari.
• Yi magana da likita a koyaushe. Wannan yana da mahimmanci musamman idan kana shan magungunan antihypertensive, kana da matsalar koda ko zuciya, ko kana da ciki ko shayarwa. Ka bi diddigin matsin jinin ka a gida idan ka fara wani kari.
• Kafofin asali su fi tasiri. Abinci mai kyau, motsa jiki, isasshen barci, rage nauyi, da rage gishiri sune manyan hanyoyi da ke da hujja mafi karfi don rage matsi.

Kammalawa

Wannan meta‑analysis ta ƙara wani ƙarin bayani, ko da yake ɗan ƙanƙanta, ga tattaunawar NMN. Ta nuna ƙaramin ragi a diastolic da kuma yiwuwar ragi a systolic ga manya, amma adadi ƙanana ne, an yi amfani da samfurin “common‑effects”, kuma sakamakon ya samo asali ne daga ƙungiya. A halin yanzu, NMN na zama ɗayan kayan jan hankali da ya kamata a ci gaba da bincike, ba a matsayin maganin da aka kafa don sarrafa matsi na jini ba.